DNMT1 and breast carcinoma: The initial study by van Agthoven et al. indicated that estrogen-dependent breast cancer cells (ZR-75-1), treated with DNMT inhibitor (5-azacytydine, 5-aza) followed by 4-hydroxytamoxifen, developed tamoxifen resistance that was dependent on the 5-aza dose [78].